AGENUS INC (AGEN)
US00847G8042 - Common Stock
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are...
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Which stocks are moving on Thursday?
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Which stocks are experiencing notable movement on Thursday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Thursday Sector Laggards: Sporting Goods & Activities, Biotechnology Stocks
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors.
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference.
Why Is Agenus (AGEN) Stock Down 55% Today?
Agenus stock is down on Thursday after the company provided AGEN investors with an update on a Phase 2 clinical trial meeting.
Thursday's session: gap up and gap down stocks
Thursday's session: gap up and gap down stocks
Top movers in Thursday's pre-market session
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
Agenus Announces Virtual Annual Shareholders Meeting
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024.
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Agenus Reports First Quarter 2024 Results
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy?
